Intratumoral interleukin-2 immunotherapy: Activation of tumor-infiltrating and splenic lymphocytes in vivo |
| |
Authors: | Steven M Dubinett Lisa Patrone Jeffery Tobias Alistair J Cochran Duan-Ren Wen William H McBride |
| |
Institution: | (1) Department of Medicine, Division of Pulmonary and Critical Care Medicine, UCLA School of Medicine, Wadsworth VA, W111B, Wilshire and Sawtelle Blvds., 90 073 Los Angeles, California, USA;(2) Medical Research Service, Wadsworth Veterans Administration Medical Center, Los Angeles, CA, USA;(3) Department of Pathology and Laboratory Medicine, UCLA School of Medicine, Los Angeles, USA;(4) Department of Surgery, UCLA School of Medicine, Los Angeles, USA;(5) Department of Radiation Oncology, UCLA School of Medicine, Los Angeles, USA;(6) Jonsson Comprehensive Cancer Center, UCLA School of Medicine, Los Angeles, California, USA |
| |
Abstract: | Direct intratumoral injection of interleukin-2 (IL-2) was evaluated in a murine model. Balb/c mice received 5 × 104 Line 1 alveolar carcinoma cells (L1C2) by subcutaneous injection. On the third day following tumor implantation, mice received injections of IL-2 (5 × 103–5 × 104 units) or diluent twice daily, either by i. p. or intratumoral injection, 5 days/week for 3 weeks. Intratumoral injection of 5 × 104 units IL-2 significantly reduced tumor volume (P <0.05 versus control), increased median survival time (P = 0.0001), and resulted in a 23.5% cure rate (P = 0.008). There were no long-term survivors in the other treatment groups. Both tumor-infiltrating lymphocytes (TIL) and splenic lymphocytes isolated directly from IL-2-treated mice demonstrated enhanced cytolytic activity compared to diluent-treated controls. To determine whether non-T-cell-mediated antitumor responses were active in our model, intratumoral immunotherapy was evaluated in athymic Balb/cnu/nu mice. In order to decrease the recruitment of lymphocyte precursors, nude mice were splenectomized and received cyclophosphamide prior to tumor injection and IL-2 therapy. Intratumoral IL-2 immunotherapy also significantly decreased tumor volume in these immunodeficient mice (P <0.02), but did not lead to long-term survival. We conclude that both TIL and splenic lymphocytes are activated in vivo in response to intratumoral IL-2 immunotherapy, suggesting that intratumoral therapy with IL-2 activates both local and systemic antitumor responses.Supported by the Tobacco-Related Disease Research Program of the University of California, the Cancer Research Coordinating Committee, the Jonsson Cancer Center Foundation, and Veterans Administration Medical Research Funds |
| |
Keywords: | Interleukin-2 Immunotherapy Tumorinfiltrating lymphocytes |
本文献已被 SpringerLink 等数据库收录! |
|